Skip to content

EBITDA at other companies

Eli Lilly logo
Eli LillyLLY
Pfizer logo
PfizerPFE
Johnson & Johnson logo
Johnson & JohnsonJNJ
Amgen logo
AmgenAMGN
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
Cardinal Health logo
Cardinal HealthCAH

Other financials

Income statement

See full
Revenue$15.0B+12.4%
Gross profit$10.8B+15.4%
Operating income$4.0B+6.9%
Net income$695.0M-46.0%
EPS (diluted)$0.39-45.8%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$382.49B+3.8%
P/E105.2×+17.4×
P/S6.1×-0.3×

Profitability

See full
Gross margin70.7%0.0pp
Operating margin24.4%
Net margin5.8%-1.5pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Calculated from AbbVie’s reported figures.

$4.0Bebit+
$1.9BDepreciation Depletion & Amortization
=$5.93B

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbbVie's EBITDA?
AbbVie (ABBV) reported EBITDA of $5.93B in Q1 2026.
How has AbbVie's EBITDA changed year-over-year?
AbbVie's EBITDA increased by 2.7% year-over-year, from $5.77B to $5.93B.
What is the long-term trend for AbbVie's EBITDA?
Over 3 years (2021 to 2025), AbbVie's EBITDA has grown at a -4.2% compound annual growth rate (CAGR), from $26.44B to $23.28B.
What does EBITDA mean?
Operating cash profit before interest, taxes, and non-cash charges.
How do you interpret EBITDA?
Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
How does EBITDA compare across companies?
Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.